TY - JOUR
T1 - UHPLC-MS/MS analysis of cannabidiol metabolites in serum and urine samples.:
T2 - Application to an individual treated with medical cannabis
AU - Pichini, Simona
AU - Malaca, Sara
AU - Gottardi, Massimo
AU - Pérez-Acevedo, Ana Pilar
AU - Papaseit, Esther
AU - Perez-Maña, Clara
AU - Farré, Magí
AU - Pacifici, Roberta
AU - Tagliabracci, Adriano
AU - Mannocchi, Giulio
AU - Busardò, Francesco Paolo
N1 - Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2021/2/1
Y1 - 2021/2/1
N2 - No analytical assay is currently available for the simultaneous determination of CBD major metabolites in serum or urine samples of individuals treated with medical cannabis or CBD-based pharmaceuticals. We developed and validated a method using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC–MS/MS) for quantifying cannabidiol (CBD) and its metabolites, cannabidiol-7-oic acid (7-COOH-CBD), 7- hydroxycannabidiol (7-OH-CBD), 6-alpha-hydroxycannabidiol (6-α–OH–CBD) and 6-beta-hydroxycannabidiol (6-β–OH–CBD) in serum and urine samples of an individual treated with medical cannabis. The ionization was performed by electrospray in negative mode to reach the sensitivity required to detect trace amounts, with limits of quantification ranging from 0.05 to 0.1 ng/mL. The method is accurate (average inter/intra-day error, <15%), precise (inter/intra-day imprecision, <15%) and fast (8 min run time) and it is an essential tool to investigate CBD pharmacokinetics and pharmacodynamics in individuals treated with medical cannabis or with CBD-based medical preparations.
AB - No analytical assay is currently available for the simultaneous determination of CBD major metabolites in serum or urine samples of individuals treated with medical cannabis or CBD-based pharmaceuticals. We developed and validated a method using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC–MS/MS) for quantifying cannabidiol (CBD) and its metabolites, cannabidiol-7-oic acid (7-COOH-CBD), 7- hydroxycannabidiol (7-OH-CBD), 6-alpha-hydroxycannabidiol (6-α–OH–CBD) and 6-beta-hydroxycannabidiol (6-β–OH–CBD) in serum and urine samples of an individual treated with medical cannabis. The ionization was performed by electrospray in negative mode to reach the sensitivity required to detect trace amounts, with limits of quantification ranging from 0.05 to 0.1 ng/mL. The method is accurate (average inter/intra-day error, <15%), precise (inter/intra-day imprecision, <15%) and fast (8 min run time) and it is an essential tool to investigate CBD pharmacokinetics and pharmacodynamics in individuals treated with medical cannabis or with CBD-based medical preparations.
KW - Cannabinoids
KW - CBD metabolites
KW - Medical cannabis
KW - Serum
KW - UHPLC-MS/MS
KW - Urine
UR - http://www.scopus.com/inward/record.url?scp=85092662930&partnerID=8YFLogxK
U2 - 10.1016/j.talanta.2020.121772
DO - 10.1016/j.talanta.2020.121772
M3 - Article
C2 - 33298281
AN - SCOPUS:85092662930
SN - 0039-9140
VL - 223
JO - Talanta
JF - Talanta
IS - Part 2
M1 - 121772
ER -